EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

Summary

Pneumonia is one of the most common infectious diseases and is caused by infectious agents such as bacteria, viruses, and fungi. Pneumonia is an acute respiratory infection that inflames the alveoli (air sacs) in the lungs through fluid or pus. The inflamed alveoli causes limited oxygen intake in the lungs and breathing difficulties for individuals, manifesting in symptoms of coughing, chest pain, and fever. Pneumonia is a major public health concern in both developed and developing countries.


Chronic diseases such as asthma, chronic obstructive pulmonary disease, and heart disease increase the risk of developing pneumonia. Elderly patients (65 years and older) have twice the incidence of hospital-acquired pneumonia compared with the adult population. Additionally, tobacco smoking has been identified as a cause of pneumonia.


In 2012, the 6MM (US, France, Germany, Italy, Spain, UK) had 4,184,449 incident cases of CAP, with 82% of that occurring in the US. By 2022, GlobalData epidemiologists forecast there will be 4,670,664 incident cases of CAP in the 6MM. In Japan, there were 40,043 cases of CAP and HAP with an annual growth rate (AGR) of 3.78%.


These 7MM are important markets for CAP and HAP during the next 10 years because these countries have a growing older population. Pneumonia incidence differs between countries, possibly due to socioeconomic factors, differences in infectious disease reporting, and heterogeneity of diagnostics. From a public health perspective, effective prevention and treatment measures should be in place to avoid disease transmission and reduce the incidence of pneumonia.

Scope

- The Gram-Negative Bacterial Pneumonia EpiCast Report provides an overview of the risk factors and epidemiological trends for pneumonia, with a focus on gram-negative bacteria, in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of incident cases of community-acquired pneumonia (CAP) segmented by sex and age (in five-year increments beginning at 0 years and ending at =85 years), incident cases of hospital-acquired pneumonia (HAP), and incident cases of ventilator-associated pneumonia (VAP). Incident HAP cases are further segmented by causative pathogens (Acinetobacter, Escherichia coli, Klebsiella, and Pseudomonas) and antibiotic resistance in these markets.
- The gram-negative bacterial pneumonia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global pneumonia market.

- Quantify patient populations in the global pneumonia market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pneumonia therapeutics in each of the markets covered.

Table Of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.2.1 Chronic Diseases Increase the Risk of Developing Pneumonia 9
3.2.2 Immunosuppressive Diseases Increase Risk of Pneumonia and Heightens Mortality 10
3.2.3 Adults are Less at Risk for HAP Compared with Elderly Patients and Children 11
3.2.4 Current Smokers Have 1.88 Greater Odds of Developing CAP 11
3.3 Forecast Methodology 12
3.3.1 Sources Used 13
3.3.2 Sources Not Used 20
3.3.3 Forecast Assumptions and Methods 20
3.4 Epidemiological Forecast of Pneumonia (2012-2022) 26
3.4.1 US 26
3.4.2 5EU 30
3.4.3 Japan 39
3.5 Discussion 43
3.5.1 Epidemiological Forecast Insight 43
3.5.2 Limitations of the Analysis 43
3.5.3 Strengths of the Analysis 44
4 Appendix 45
4.1 Bibliography 45
4.2 About the Authors 49
4.2.1 Epidemiologists 49
4.2.2 Reviewers 49
4.2.3 Global Director of Epidemiology and Health Policy 51
4.2.4 Global Head of Healthcare 52
4.3 About GlobalData 53
4.4 About EpiCast 53
4.5 Disclaimer 53

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Pneumonia 9
Table 2: Sources of CAP Incidence Data Used in the Epidemiology Forecast 12
Table 3: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 26
Table 4: US, Incident Cases of CAP, N, by Age, Sex, N (Row %), 2012 27
Table 5: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N (Pathogen-Specific %), 2012 28
Table 6: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Multidrug and Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 29
Table 7: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 30
Table 8: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 31
Table 9: 5EU, Incident Cases of CAP, All Ages, by Sex, N (Row %), 2012 33
Table 10: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34
Table 11: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35
Table 12: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N (Pathogen-Specific %), 2012 36
Table 13: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N (Pathogen-Specific %), 2012 37
Table 14: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen and Multidrug/Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 38
Table 15: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39
Table 16: Japan, Incident Cases of CAP and HAP, by Age, Sex, N (Row %), 2012 40
Table 17: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N (Pathogen-Specific %), 2012 41
Table 18: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Antibiotic Resistance, N and Percentage of Pathogen-Specific Cases, 2012 42

1.2 List of Figures
Figure 1: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 27
Figure 2: US, Incident Cases of CAP, N, by Age, Sex, N, 2012 28
Figure 3: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N, 2012 29
Figure 4: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 31
Figure 5: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 32
Figure 6: 5EU, Incident Cases of CAP, All Ages, by Sex, N, 2012 33
Figure 7: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34
Figure 8: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35
Figure 9: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N, 2012 36
Figure 10: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N, 2012 37
Figure 11: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39
Figure 12: Japan, Incident Cases of CAP and HAP, by Age, Sex, N, 2012 40
Figure 13: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N, 2012 41

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.